Mr. Silberg is a seasoned professional in the Healthcare Industry with substantial executive level experience in major branded pharmaceuticals, medium sized biotech, start-up biotech and generic IV drug manufacturing and commercialization. He has led multiple strategic transactions including a company divestiture, a public company spin out, asset acquisitions and partnerships. He has consistently grown both revenue and earnings characterized most recently by APP Pharmaceuticals revenue growth of 23.1% compound annual growth rate (2005-2009). His leadership skills have guided companies through many organizational challenges ranging from building a start-up biotech company to integrating a North America based company with a European based global healthcare organization. He has successfully managed numerous company reorganizations targeted at process improvement, creating new capabilities, building needed infrastructure and downsizing.
Mr. Silberg most recently served as President and CEO of APP North America, a wholly-owned subsidiary of Fresenius Kabi, a global healthcare company based in Germany. Prior to the Fresenius acquisition of APP, he served as President and CEO of APP Pharmaceuticals, a publicly traded company. During his tenure at APP, Mr. Silberg restructured the management team and reorganized the company into Business Units focused on strategic growth by therapeutic categories which led to APP growing to become the number two generic injectable company in the US in 2009. Prior to APP, he served as the COO and built commercial organizations for both Tercica, Inc., a biotech company in San Francisco, and Ligand Pharmaceuticals, Inc., a midsized biotech company based in San Diego. He led the Ligand team in launching four new products and in completing a major acquisition.
Mr. Silberg’s career began in 1972 with Hoffmann La Roche, Inc. where he started in sales and advanced to VP of Business Operations. During his 27 years with Roche, he was instrumental in multiple product launches and redesigned the Market Intelligence function. He conceived, created and led a new department: Health Systems Management, which ultimately led to restructuring the entire Roche US commercial organization in 1995.
Mr. Silberg is a member of the Board of Directors of GenWay. He also serves on the Boards of a number of other corporate and philanthropic organizations. He received his BS from the University of Minnesota.
